重组人促血小板生成素治疗急性白血病化疗后血小板减少的效果观察  

Effect observation of recombinant human thrombopoietin in treatment of thrombocytopenia caused by chemotherapy of acute leukemia

作　　者：章志学[1] 肖牛明[1] 肖小芳[1] 谢将 肖文琼[1] 

机构地区：[1]江西省吉安市中心人民医院血液科,江西吉安343000

出　　处：《中国当代医药》2014年第28期91-93,共3页China Modern Medicine

摘　　要：目的：探讨重组人促血小板生成素（rhTPO）治疗急性白血病化疗后血小板减少的临床效果。方法选取2012年1月～2014年1月在本院接受化疗治疗且发生血小板减少症的急性白血病患者56例，将其随机分为观察组和对照组，每组各28例。观察组给予rhTPO治疗，对照组给予重组人白介素-11（rhIL-11）治疗，比较两组的疗效。结果观察组治疗后的血小板水平明显高于对照组，且血小板〈50×10^9/L的持续时间、恢复至70×10^9/L和100×10^9/L所需时间明显短于对照组（P〈0.05）；观察组的不良反应发生率明显低于对照组（3.6% vs 42.8%）（P〈0.05）。结论 rhTPO治疗急性白血病化疗后血小板减少的效果显著，安全性高，值得临床推广应用。Objective To investigate the clinical effect of recombinant human thrombopoietin （rhTPO） in the treatment of thrombocytopenia caused by chemotherapy of acute leukemia. Methods Fifty-six patients who received chemothera-py and suffered from thrombocytopenia due to it in our hospital were selected and randomly divided into the observation group （n=28） and the control group （n=28）.The observation group received rhTPO treatment and the control group received recombinant human interleukin-11 （rhIL-11） treatment.The efficacy of the two groups was compared. Results After treatment,the platelet level in the observation group was significantly higher than that in the control group,and duration of platelets〈50×10^9/L and time of platelet returning to 70×10^9/L and 100×10^9/L in the observation group were significantly shorter than those in the control group （P〈0.05）.The incidence rate in the the observation group was obvi-ously lower than that in the control group （3.6% vs 42.8%） （P〈0.05）. Conclusion In the treatment of thrombocytopenia caused by chemotherapy of acute leukemia,rhTPO shows remarkable effects and high safety,thereby it is worthy of clinical promotion and application.

关 键 词：急性白血病 血小板减少 重组人促血小板生成素 

分 类 号：R733.71[医药卫生—肿瘤]